These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3104275)

  • 21. Resistance of Pseudomonas aeruginosa to imipenem is independent of beta-lactamase production.
    Büscher KH; Cullmann W; Opferkuch W
    J Antimicrob Chemother; 1987 May; 19(5):700-1. PubMed ID: 3112097
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
    Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
    Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of cross-resistance between imipenem and other beta-lactam antibiotics for Pseudomonas aeruginosa.
    Opferkuch W; Cullmann W
    Eur J Clin Microbiol; 1987 Jun; 6(3):330-2. PubMed ID: 3113943
    [No Abstract]   [Full Text] [Related]  

  • 25. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and antibiotic susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae in Estonian intensive care units in comparison with European data.
    Lõivukene K; Sepp E; Adamson V; Mitt P; Kallandi U; Otter K; Naaber P
    Scand J Infect Dis; 2006; 38(11-12):1001-8. PubMed ID: 17148068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of garlic oil and four diallyl sulphides against antibiotic-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Tsao S; Yin M
    J Antimicrob Chemother; 2001 May; 47(5):665-70. PubMed ID: 11328781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative bactericidal activity of imipenem and other antibiotics against Pseudomonas aeruginosa].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1988 May; 36(5):472-6. PubMed ID: 3136428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. beta-Lactamase Id of ceftazidime-resistant Pseudomonas aeruginosa strains.
    Michel-Briand Y; Nicolas T; Godard C; Plesiat P
    Microbiologica; 1992 Jan; 15(1):65-9. PubMed ID: 1556960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro antibacterial activity and beta-lactamase stability of meropenem].
    Poiată A; Tuchiluş C; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):589-94. PubMed ID: 14756067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.
    Torrens G; Cabot G; Ocampo-Sosa AA; Conejo MC; Zamorano L; Navarro F; Pascual Á; Martínez-Martínez L; Oliver A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6407-10. PubMed ID: 27480848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imipenem resistance in Pseudomonas aeruginosa is due to diminished expression of outer membrane proteins.
    Büscher KH; Cullmann W; Dick W; Wendt S; Opferkuch W
    J Infect Dis; 1987 Oct; 156(4):681-4. PubMed ID: 3114392
    [No Abstract]   [Full Text] [Related]  

  • 36. [Characterization of imipenem resistance in Pseudomonas aeruginosa: decreased phenotypic expression of outer membrane proteins D1 and D2].
    Cullmann W; Büscher KH; Opferkuch W
    Immun Infekt; 1986 Nov; 14(6):227-9. PubMed ID: 3100427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-Frequency transduction of imipenem resistance and high-frequency transduction of ceftazidime and aztreonam resistance by the bacteriophage AP-151 isolated from a Pseudomonas aeruginosa strain.
    Blahová J; Králiková K; Krcméry V; Jezek P
    J Chemother; 2000 Dec; 12(6):482-6. PubMed ID: 11154029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
    Watanabe Y; Fujiue Y; Yano S; Shimizu S; Muroki K; Doi M; Kuwabara M
    Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [